Showing 1 - 10 of 56
The dynamics of drug launch has been an under-researched area. Most of the studies in this field focus on developed countries, quite uniform in terms of disease profile and regulatory framework, and analyse whether stringency in regulation influences launch delay. Developing countries, in...
Persistent link: https://www.econbiz.de/10011291802
In this paper, I examined how the People's Republic of China (PRC) and India, two largest transitional economies in Asia, have engaged in improving their innovation capability in the economic transition. First, I measured and compared innovation capability of both countries by using not only...
Persistent link: https://www.econbiz.de/10011944193
A comparative study is undertaken that explores Chinese and Indian pharmaceutical industries under different patent regimes. It is found that relative to India, which had implemented process patent until 2005, China with a product patent regime since 1993 suffers from both lower drug...
Persistent link: https://www.econbiz.de/10010273457
This paper attempts to evaluate the possible gains and losses arising from the gradual opening up of pharmaceutical trade between India and Pakistan. We explain the comparative advantages of both countries at a disaggregated level, followed by a qualitative analysis of various perceptions and...
Persistent link: https://www.econbiz.de/10011807697
The auto sector in Pakistan has been a persistent opponent of trade liberalisation in the country. This has entailed losses to consumers in terms of higher prices, low safety and quality standards, and lack of innovation in this sector. The deletion programme, which was to result in...
Persistent link: https://www.econbiz.de/10011807699
Both China and India, the emerging giants in Asia, have achieved significant economic development in recent years. China has enjoyed a high annual GDP growth rate of 10 per cent and India has achieved an annual GDP growth rate of 6 per cent since 1981. Decomposing China and India’s GDP growth...
Persistent link: https://www.econbiz.de/10010284745
A comparative study is undertaken that explores Chinese and Indian pharmaceutical industries under different patent regimes. It is found that relative to India, which had implemented process patent until 2005, China with a product patent regime since 1993 suffers from both lower drug...
Persistent link: https://www.econbiz.de/10003725601
The article tries to assess the utilization efficiency of capacity of Indian rubber industry in terms of econometric framework for the period,1979-80 to 2008-09.Capacity output has been obtained at the minimum point of short run average cost curve. The result suggests that there has been...
Persistent link: https://www.econbiz.de/10009491960
The dynamics of drug launch has been an under-researched area. Most of the studies in this field focus on developed countries, quite uniform in terms of disease profile and regulatory framework, and analyse whether stringency in regulation influences launch delay. Developing countries, in...
Persistent link: https://www.econbiz.de/10011303838
Today, the global pharmaceutical product value chain is becoming increasingly complex and this has led to the emergence of 'multiple quality standards' for medicines. But this non-uniformity in the quality of medicine is also contingent upon both the regulatory milieu in the country of...
Persistent link: https://www.econbiz.de/10011337690